Opendata, web and dolomites

AcTaferon

Revitalizing the clinical potential of type I IFNs in fighting influenza A virus infections with AcTaferon.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AcTaferon project word cloud

Explore the words cloud of the AcTaferon project. It provides you a very rough idea of what is the project "AcTaferon" about.

pilot    doses    fundamental    unveils    antitumor    effect    therapeutic    en    diseases    models    background    threat    health    fusing    ing    infection    preliminary    ifn    biological    pandemics    causing    occasional    recognizes    negatively    pipeline    based    site    uz    body    tumor    academic    interdisciplinary    eacute    respectively    serious    substantial    receptors    influenza    morbidity    interferons    actaferons    drugs    binding    drug    vivo    extend    cells    broaden    miracle    regulate    desired    intracellular    actaferon    opportunity    transferred    combining    clinical    obstacles    efficient    severe    concentration    interferon    underscore    viruses    saelens    cytokine    activated    circumvents    limited    hence    expertise    administrable    affinity    marker    co    tackle    fight    antiviral    innovative    vitro    surface    regression    huge    asset    epidemics    prof    remained    route    industrial    orionis    cellular    seasonal    inactive    strategy    moiety    offers    company    ifns    influence    viral    limits    too    mutant    receptor    sensitivity    cancer    mortality   

Project "AcTaferon" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.cordis.europa.eu/project/rcn/209395_en.html
 Total cost 144˙230 €
 EC max contribution 144˙230 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 144˙230.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Based on their antiviral and antitumor effect, type I interferons (IFNs) were believed to be the miracle drug to tackle viruses and cancer. However, clinical IFN applications remained limited due to severe side effects resulting from widespread cellular sensitivity to IFN, which limits the administrable doses. Hence, the drug concentration at the desired infection or tumor site is often too low to be fully therapeutic efficient. AcTaferon (Activated-by-Targeting interferon), co-developed by Prof. Uzé, circumvents these obstacles. By fusing an IFN mutant with strongly reduced receptor binding affinity to a targeting moiety that recognizes a surface marker on specific cells, AcTaferon remains inactive “en route” through the body and unveils its biological activity only on specific target cells. Robust tumor regression without side effects and preliminary antiviral effects underscore the huge clinical potential of AcTaferon to fight cancer and viral diseases. By combining the AcTaferon and influenza expertise of Prof. Uzé and Prof. Saelens, respectively, this interdisciplinary project offers the opportunity to broaden the innovative AcTaferon therapeutic strategy from the cancer to the viral infection field. Influenza A was selected as a pilot target as seasonal influenza A epidemics and occasional pandemics remain a serious health threat causing substantial morbidity and mortality. Influenza A-targeted AcTaferons will be developed and analyzed in relevant in vitro and in vivo models. Eventually, all knowledge will be transferred to Orionis, a company that will implement the AcTaferon technology to develop novel drugs. My background on the intracellular processes that negatively regulate cytokine receptors and hence influence the cellular sensitivity to a (therapeutic) cytokine is an asset to this project. I will be able to extend my fundamental research experience with applied cytokine research, which may extend into a new academic or industrial research pipeline.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACTAFERON" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ACTAFERON" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EcoSpy (2018)

Leveraging the potential of historical spy satellite photography for ecology and conservation

Read More  

Migration Ethics (2019)

Migration Ethics

Read More  

DEAP (2019)

Development of Epithelium Apical Polarity: Does the mechanical cell-cell adhesions play a role?

Read More